Summary:
Click image to enlarge
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with mild Alzheimer's disease or amnestic mild cognitive impairment (MCI). We are actively recruiting for Alzheimer's and Mild Cognitive Impairment (MCI) patients for this study.
Qualified Participants Must:
• Be suffering from Alzheimers or Mild Cognitive Impairment
•
Be between 40 and 85 years old
•
Be a non-smoker or ex-smoker
•
Not be currently on AD medications or willing to tolerate a 1 month washout period with physician approval
•
Be willing to travel to Newark, New Jersey for an in-house 10-day, 11-night study with 1 end-of-study visit
Qualified Participants May Receive:
Compensation for travel and accommodations during the trial.